logo-loader
viewOragenics Inc

Oragenics working on treatment for oral mucositis with promising AG013 product

Oragenics (NYSE: OGEN) CEO Alan Joslyn talked with Proactive’s Steve Darling at the 12th annual LD Micro Conference. The Tampa, Florida, company develops antibiotics against infectious diseases. It is developing AG013, which is in clinical trials for the treatment of oral mucositis, or ulcerative lesions in patients with cancer. 

Quick facts: Oragenics Inc

Price: 0.4502 USD

NYSE:OGEN
Market: NYSE
Market Cap: $20.77 m
Follow

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Bulls, Bears & Brokers: Alto Capital’s Tony Locantro on Nyrada IPO and small...

Alto Capital investment manager and stock market commentator Tony Locantro updates Proactive on this week's listing of Nyrada Inc (ASX:NYR), a spin-off of Noxopharm Ltd’s (ASX:NOX). He discusses the reasons for the spin-off, including some of the recent and expected trading patterns. Locantro...

1 week, 1 day ago

2 min read